Developing drugs for cognitive impairment in schizophrenia

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

There are strong data suggesting that improvement in the cognitive impairment associated with schizophrenia will contribute to enhanced functional outcomes for patients with this illness. Measurement and Treatment Research to Improve Cognition in Schizophrenia was established to provide a pathway for developing and registering potential cognitive-enhancing agents for this condition by addressing issues related to the content of the cognitive assessment battery and the clinical design features to be used in registration studies. This article examines key challenges related to the actual clinical development of cognitive-enhancing agents. These challenges include improving the probability of technical success and attrition rates of candidate molecules, establishing better animal models of human cognition, and developing biomarkers to decrease development costs and increase the speed of the clinical discovery process. Biomarkers are important for molecular target validation, dose selection, surrogate end points, and population segmentation. Examples of approaches for the development of agents for cognitive impairment associated with schizophrenia are discussed. It is concluded that close collaboration among academia, the National Institutes of Health, regulatory bodies, and industry will be important to advance the goal of developing drugs for this important condition.

Original languageEnglish (US)
Pages (from-to)816-822
Number of pages7
JournalSchizophrenia Bulletin
Volume31
Issue number4
DOIs
StatePublished - Oct 2005

Fingerprint

Schizophrenia
Biomarkers
Cognition
Pharmaceutical Preparations
National Institutes of Health (U.S.)
Industry
Animal Models
Costs and Cost Analysis
Research
Population
Cognitive Dysfunction
Therapeutics

Keywords

  • Acetylcholine
  • Biomarkers
  • Functional outcomes
  • Surrogate end points
  • Targeted therapeutics

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Neuroscience(all)

Cite this

Developing drugs for cognitive impairment in schizophrenia. / Breier, Alan.

In: Schizophrenia Bulletin, Vol. 31, No. 4, 10.2005, p. 816-822.

Research output: Contribution to journalArticle

@article{e6d1b81934b2414d95e9390b7a5b41d0,
title = "Developing drugs for cognitive impairment in schizophrenia",
abstract = "There are strong data suggesting that improvement in the cognitive impairment associated with schizophrenia will contribute to enhanced functional outcomes for patients with this illness. Measurement and Treatment Research to Improve Cognition in Schizophrenia was established to provide a pathway for developing and registering potential cognitive-enhancing agents for this condition by addressing issues related to the content of the cognitive assessment battery and the clinical design features to be used in registration studies. This article examines key challenges related to the actual clinical development of cognitive-enhancing agents. These challenges include improving the probability of technical success and attrition rates of candidate molecules, establishing better animal models of human cognition, and developing biomarkers to decrease development costs and increase the speed of the clinical discovery process. Biomarkers are important for molecular target validation, dose selection, surrogate end points, and population segmentation. Examples of approaches for the development of agents for cognitive impairment associated with schizophrenia are discussed. It is concluded that close collaboration among academia, the National Institutes of Health, regulatory bodies, and industry will be important to advance the goal of developing drugs for this important condition.",
keywords = "Acetylcholine, Biomarkers, Functional outcomes, Surrogate end points, Targeted therapeutics",
author = "Alan Breier",
year = "2005",
month = "10",
doi = "10.1093/schbul/sbi051",
language = "English (US)",
volume = "31",
pages = "816--822",
journal = "Schizophrenia Bulletin",
issn = "0586-7614",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Developing drugs for cognitive impairment in schizophrenia

AU - Breier, Alan

PY - 2005/10

Y1 - 2005/10

N2 - There are strong data suggesting that improvement in the cognitive impairment associated with schizophrenia will contribute to enhanced functional outcomes for patients with this illness. Measurement and Treatment Research to Improve Cognition in Schizophrenia was established to provide a pathway for developing and registering potential cognitive-enhancing agents for this condition by addressing issues related to the content of the cognitive assessment battery and the clinical design features to be used in registration studies. This article examines key challenges related to the actual clinical development of cognitive-enhancing agents. These challenges include improving the probability of technical success and attrition rates of candidate molecules, establishing better animal models of human cognition, and developing biomarkers to decrease development costs and increase the speed of the clinical discovery process. Biomarkers are important for molecular target validation, dose selection, surrogate end points, and population segmentation. Examples of approaches for the development of agents for cognitive impairment associated with schizophrenia are discussed. It is concluded that close collaboration among academia, the National Institutes of Health, regulatory bodies, and industry will be important to advance the goal of developing drugs for this important condition.

AB - There are strong data suggesting that improvement in the cognitive impairment associated with schizophrenia will contribute to enhanced functional outcomes for patients with this illness. Measurement and Treatment Research to Improve Cognition in Schizophrenia was established to provide a pathway for developing and registering potential cognitive-enhancing agents for this condition by addressing issues related to the content of the cognitive assessment battery and the clinical design features to be used in registration studies. This article examines key challenges related to the actual clinical development of cognitive-enhancing agents. These challenges include improving the probability of technical success and attrition rates of candidate molecules, establishing better animal models of human cognition, and developing biomarkers to decrease development costs and increase the speed of the clinical discovery process. Biomarkers are important for molecular target validation, dose selection, surrogate end points, and population segmentation. Examples of approaches for the development of agents for cognitive impairment associated with schizophrenia are discussed. It is concluded that close collaboration among academia, the National Institutes of Health, regulatory bodies, and industry will be important to advance the goal of developing drugs for this important condition.

KW - Acetylcholine

KW - Biomarkers

KW - Functional outcomes

KW - Surrogate end points

KW - Targeted therapeutics

UR - http://www.scopus.com/inward/record.url?scp=26444440565&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=26444440565&partnerID=8YFLogxK

U2 - 10.1093/schbul/sbi051

DO - 10.1093/schbul/sbi051

M3 - Article

C2 - 16150959

AN - SCOPUS:26444440565

VL - 31

SP - 816

EP - 822

JO - Schizophrenia Bulletin

JF - Schizophrenia Bulletin

SN - 0586-7614

IS - 4

ER -